ArticlePediatric blood & cancer2014

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.

Robin E Norris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.